Very-High-Dose Methadone With Minimal Toxicity and Inadequate Pain Control in a Hospice Patient With Cancer

REFERENCES

• Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001;9:73–83.
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153–1193.
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Lewkowiez L, Hays H, Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501–504.
   PubMed Web of Science ®Google Scholar
• Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J Psychoactive Drugs. 1999;31:95–102.
   PubMed Web of Science ®Google Scholar
• Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis. 2002;21:1–12.
   PubMed Web of Science ®Google Scholar
• Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19: 13–24.
   PubMedGoogle Scholar
• Melichar B, Zezulova M. The significance of altered gastrointestinal permeability in cancer patients. Curr Opin Support Palliat Care. 2011;5:47–54.
   PubMedGoogle Scholar
• Shaw MT, Spector MH, Ladman AJ. Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. Cancer Treat Rev. 1979;6:141–151.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Goncalves CG, Meguid MM. Catabolic outcome from non-gastrointestinal malignancy-related malabsorption leading to malnutrition and weight loss. Curr Opin Clin Nutr Metab Care. 2005;8:419–427.
   PubMed Web of Science ®Google Scholar
• Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95:3374–3382.
   PubMed Web of Science ®Google Scholar
• Bauer B, Yang X, Hartz AM, In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol. 2006;70:1212–1219.
   PubMed Web of Science ®Google Scholar
• Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol. 2004;66:413–419.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol. 2004;57:600–610.
   PubMed Web of Science ®Google Scholar
• Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006;80:682–690.
   PubMed Web of Science ®Google Scholar
• Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM. Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther. 1981;29:211–217.
   PubMed Web of Science ®Google Scholar
• Prescribing information. Dolophine® Hydrochloride (methadone hydrochloride tablets, USP). Columbus, OH: Roxane Laboratories, March 2009. Available at: http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?doc Base=renetnt&folderPath=/Prescribing+Information/PIs/ Roxane/Dolophine/Dolophine+Tablets.pdf. Accessed June 2011.
   Google Scholar
• Ceciliani F, Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Pept Sci. 2007;8:91–108.
   PubMed Web of Science ®Google Scholar
• Abramson FP. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein. Clin Pharmacol Ther. 1982;32:652–658.
   PubMed Web of Science ®Google Scholar
• Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001;33:161–235.
   PubMed Web of Science ®Google Scholar
• Herve F, Duche JC, d'Athis P, Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996;6:403–415.
   PubMedGoogle Scholar
• Jolliet-Riant P, Boukef MF, Duche JC, Simon N, Tillement JP. The genetic variant A of human alpha 1-acid glycoprotein limits the blood to brain transfer of drugs it binds. Life Sci. 1998;62:PL219–PL226.
   PubMed Web of Science ®Google Scholar
• Krusekopf S, Roots I, Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol. 2003;466:7–12.
   PubMed Web of Science ®Google Scholar
• McCune JS, Hawke RL, LeCluyse EL, In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000;68:356–366.
   PubMed Web of Science ®Google Scholar
• Prescribing information. Dexamethasone Tablets, USP, Dexamethasone Oral Solution, and Dexametahsone IntensolTM Oral Solution (Concentrate). Columbus, OH: Roxane Laboratories, September 2007. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+ Information/PIs/Roxane/Dexamethasone/Dexamethasone+ Tablets+Solution+and+Intensol.pdf. Accessed June 2011.
   Google Scholar
• Borowsky SA, Lieber CS. Interaction of methadone and ethanol metabolism. J Pharmacol Exp Ther. 1978;207:123–129.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271–1294.
   PubMed Web of Science ®Google Scholar
• Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12:109–124.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Klein K, Saussele T, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743–759.
   PubMed Web of Science ®Google Scholar
• Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9:598–610.
   PubMed Web of Science ®Google Scholar
• Tolson AH, Li H, Eddington ND, Wang H. Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos. 2009;37:1887–1894.
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11: 126–135.
   PubMed Web of Science ®Google Scholar
• Layson-Wolf C, Goode JV, Small RE. Clinical use of methadone. J Pain Palliat Care Pharmacother. 2002;16: 29–59.
   PubMedGoogle Scholar
• Crettol S, Deglon JJ, Besson J, ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80:668–681.
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J Pharmacol Toxicol Methods. 1999;42:61–66.
   PubMed Web of Science ®Google Scholar
• Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med. 2008;9:315–344.
   PubMed Web of Science ®Google Scholar
• Chhabra S, Bull J. Methadone. Am J Hosp Palliat Care. 2008;25:146–150.
   PubMed Web of Science ®Google Scholar
• Bellward GD, Warren PM, Howald W, Axelson JE, Abbott FS. Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther. 1977;22:92–99.
   PubMed Web of Science ®Google Scholar
• Nilsson M-I, Widerlov E, Meresaar U, Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol. 1982;22:337–342.
   PubMed Web of Science ®Google Scholar
• Cook JD, Strauss KA, Caplan YH, Lodico CP, Bush DM. Urine pH: the effects of time and temperature after collection. J Anal Toxicol. 2007;31:486–496.
   PubMed Web of Science ®Google Scholar
• Alpern RJ, Sakhaee K. The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. Am J Kidney Dis. 1997;29:291–302.
   PubMed Web of Science ®Google Scholar